Randstad Sourceright Releases Report on Demand for Key Jobs in the US During COVID-19
This week, Randstad Sourceright released its report, “How is Key Talent in the US Impacted by COVID-19?” The report analyzes data from the Bureau of Labor Statistics, World Health Organization, job boards, career sites, and social media postings to map the demand for key jobs in the US.
The report identifies the changes in demand for key jobs across six job families between January 2019 and April 2020, one of which is chemistry (pharmaceutical R&D).
While there has been a 17% decrease in overall pharma R&D jobs from February to March, the demand for clinical research associates and trial managers has increased by 46%, making it one of the few industries that has had to increase hiring since the start of the pandemic. These were identified as the two most sought after roles in pharma R&D. It is projected that the pandemic will accelerate the shortage of talent and increase recruitment activities for these roles.
The report aims to identify the shift in demand for certain skills, which will inform employers on how to be more prepared to recruit and hire once things return to normal.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
